Over the past few years, we are witnessing a great progress in the treatment of heart failure (HF), as well as in the development of cardiac biomarkers. Intriguing interaction of various mechanisms, involving neurohumoral activation, inflammation, pressure/volume ventricular load, myocardial remodeling and myocardial lesion, lead to heart failure development. Natriuretic peptide testing is commonly used in routine clinical practice. It has a paramount role in the diagnosis and prognosis of HF as well as well-known significance in treatment-guided therapy. Knowing the complexity of HF pathophysiological process, new biomarkers have emerged that can replace the usual ones. (1-3) The aim of this paper is to compare natriuretic peptides, ST2, galectin-3, and highly sensitive troponin. It is reasonable to expect that the future will bring a multibiomarker panel as a necessary tool to improve HF understanding as well as better treatment of HF patients.